PYC THERAPEUTICS LIMITED — AGM Information 2014

Nov 26, 2014

**Phylogica 2014

AGM
Presenta7on (PYC:ASX)**

Harnessing biodiversity for peptide therapeutics

Disclaimer

The
purpose
of
the
presenta.on
is
to
provide
an
update
of
the
business
of
Phylogica
Limited
(ASX:PYC) [‘Phylogica’].
These
slides
have
been
prepared
as
a
presenta.on
aid
only
and
the
informa.on
they
contain
may require
further
explana.on
and/or
clarifica.on.
Accordingly,
these
slides
and
the
informa.on
they
contain should
be
read
in
conjunc.on
with
past
and
future
announcements
made
by
Phylogica
and
should
not
be
relied upon
as
an
independent
source
of
informa.on.
Please
contact
Phylogica
and/or
refer
to
the
Company's
website for
further
informa.on.

The
views
expressed
in
this
presenta.on
contain
informa.on
derived
from
publicly
available
sources
that
have not
been
independently
verified.
No
representa.on
or
warranty
is
made
as
to
the
accuracy,
completeness
or reliability
of
the
informa.on.

Any
forward
looking
statements
in
this
presenta.on
have
been
prepared
on
the
basis
of
a
number
of assump.ons
which
may
prove
incorrect
and
the
current
inten.ons,
plans,
expecta.ons
and
beliefs
about
future events
are
subject
to
risks,
uncertain.es
and
other
factors,
many
of
which
are
outside
Phylogica’s
control. Important
factors
that
could
cause
actual
results
to
differ
materially
from
assump.ons
or
expecta.ons expressed
or
implied
in
this
presenta.on
include
known
and
unknown
risks.
Because
actual
results
could
differ materially
to
assump.ons
made
and
Phylogica’s
current
inten.ons,
plans,
expecta.ons
and
beliefs
about
the future,
you
are
urged
to
view
all
forward
looking
statements
contained
in
this
presenta.on
with
cau.on.

This
presenta.on
should
not
be
relied
on
as
a
recommenda.on
or
forecast
by
Phylogica.
Nothing
in
this presenta.on
should
be
construed
as
either
an
offer
to
sell
or
a
solicita.on
of
an
offer
to
buy
or
sell
shares
in
any jurisdic.on.

==> picture [718 x 31] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

**2014

Highlights**

§ Successfully
validated
powerful
intracellular
drug
delivery
plaTorm § Iden.fied
‘Best-­‐in-­‐Class’
Phylomers
for
delivering
drugs
inside
cells § ‘Value-­‐adding’
strategy
to
improve
intracellular
delivery
of
exis.ng
drugs

§ Launched
proprietary
cancer
programme
(Product
Focus)

• § Announced
  collabora.on
  with
  Genentech

==> picture [64 x 41] intentionally omitted <==

==> picture [56 x 42] intentionally omitted <==

==> picture [718 x 31] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

**Corporate

Snapshot**

	Shareholders		%
	B. Hockings Sietsma Holdings Bonadido Top 15		25 8 4 55

Execu&ve
Team Dr
Richard
Hopkins
–
CEO Dr
Paul
WaQ
-­‐
CSO

	Summary
ASX		PYC
Cash (9/14)		4.7m
Net Burn		3.2m
Market Cap		16m
52 wk low/high		0.1/0.4c
Shares on issue		1000m

Board
of
Directors

==> picture [81 x 114] intentionally omitted <==

==> picture [76 x 106] intentionally omitted <==

Dr
Doug
Wilson Dr
Richard
Hopkins Non-­‐Execu7ve
Chairman CEO

==> picture [83 x 115] intentionally omitted <==

Jeremy
Curnock-­‐Cook NED

==> picture [92 x 114] intentionally omitted <==

Dr
Bernard
Hockings NED

==> picture [106 x 114] intentionally omitted <==

Bruce
McHarrie NED

==> picture [130 x 29] intentionally omitted <==

4

**Phylogica:

focussed
on
intracellular
delivery
of
biologics**

==> picture [77 x 35] intentionally omitted <==

==> picture [719 x 393] intentionally omitted <==

----- Start of picture text -----

CNS Delivery
Cell penetrating Intracellular Drug
Vaccines
peptides Delivery
Cancer
Antimicrobials
Differen7a7on
Product
Focus
----- End of picture text -----

==> picture [130 x 29] intentionally omitted <==

5

**Technology

Update**

**Majority

of
drug
targets
are
inside
cells**

**Intracellular

Drug
Targets**

Small
Molecule
Drugs
(10%) Undrugged
targets
(90%) Biologics?

§ PYC
addressing
unmet
need
to
deliver
biologic
drugs inside
cells!

==> picture [718 x 31] intentionally omitted <==

**Pep7des:

purpose
built
for
the
job**

==> picture [545 x 340] intentionally omitted <==

----- Start of picture text -----

Large
Biologics
(Smart
drugs)
Cell
Penetra7ng
Phylomer
Pep7des
Specific
(Biologic)
Small
Molecule
Drugs
Size
Targets
----- End of picture text -----

==> picture [130 x 29] intentionally omitted <==

8

**delivering

biologics
cargoes
inside
cells**

==> picture [604 x 397] intentionally omitted <==

**Poten7al
to
expand
the
druggable
landscape
by

10-­‐fold!!**

==> picture [718 x 31] intentionally omitted <==

----- Start of picture text -----

9
----- End of picture text -----

**Valida7on

of ‘Best
in
Class’
Phylomers
for intracellular
drug
delivery**

10

**‘Best-­‐in-­‐class’

Phylomers
for
delivering
drugs
inside cells**

==> picture [603 x 340] intentionally omitted <==

----- Start of picture text -----

25-­‐fold
High
receptor-­‐expressing
cells:
50 transfec.on
efficiency:
70.3%
10µM protein
40 3µM protein
30
‘Best
in
Class’
Phylomer
CPP
20
10
0
HisMBP PYC35_RBD_S11 TAT_RBD_S11PYC-FPP-3_RBD_S11PYC-FPP-2_RBD_S11PYC-FPP-4_RBD_S11PYC-FPP-1_RBD_S11
single cell population(%
Green
Cells)
Delivery
efficiency
% green viable cells (Q3)
----- End of picture text -----

§ Phylomers
improve
intracellular
drug
deliver
25-­‐50
X § Phylomers
are
up
to
37-­‐X
befer
than
previous
cell
penetra.ng
gold
standard

==> picture [130 x 29] intentionally omitted <==

27/11/14

11

**Applica7ons

for
Phylogica’s ‘Best-­‐in-­‐Class’
Drug
Deliver
Solu7on**

12

**Mul7ple

commercialis7on
opportuni7es**

==> picture [164 x 109] intentionally omitted <==

‘Value
Adding’ Improve
delivery
of
exis.ng drugs

Cell
Penetra.ng Phylomers

==> picture [164 x 92] intentionally omitted <==

‘Phylomer
Therapeu?cs’ Fully
integrated
drug
delivery/ discovery
plaTorm

==> picture [87 x 86] intentionally omitted <==

Plalorm Products

==> picture [130 x 29] intentionally omitted <==

13

**Value

Adding:
Approaching
key
potency
thresholds**

	Phylomer CPPs_toxins <1µM = key potency threshold Phylomer CPPs_cargoes Standard CPP_Cargoes Compe7tors

==> picture [130 x 29] intentionally omitted <==

14

**Phylogica’s

Oncology
Programme Targe7ng
Breat
Cancer**

15

**Developing

Phylomer
drugs
to
treat
cancer**

§ Unmet
need
for
drugs
against
breast
cancer
targets intractable
to
conven.onal
therapies

§ Phylogica’s
plaTorm
accelerates
path
to
drug
discovery

§ Rapid
access
to
high-­‐value
commercial
inflexion
points

==> picture [130 x 29] intentionally omitted <==

16

**Phylogica’s

Proprietary
Oncology
Programme**

Func7onal Program Indica7on Discovery Preclinical Valida7on Stat
5/3 Breast
Cancer Myc Breast
Cancer YB1 Breast
Cancer

==> picture [718 x 31] intentionally omitted <==

**Upcoming

commercial
milestones**

§ Discovery
Partnerships

– Genentech
II
(2014/15)

– New
discovery
alliances

– Cosmeceu.cal
out-­‐license
(Biolink)

§ **Oncology

programme**

• Early
  2015: In
  vitro data
  –
  important
  early-­‐stage
  partnering opportunity.

• Late
  2015: In
  vivo data
  -­‐
  Licensing
  opportunity

==> picture [130 x 29] intentionally omitted <==

18

**A

Big
Thankyou
To
All
PYC
Staff!!!!!**

==> picture [130 x 29] intentionally omitted <==

19

Summary

§ World
leaders
in
pep.de-­‐based
intracellular
drug
delivery

§ Combined
with
Phylogica’s
powerful
Drug
Discovery
technology
to develop
fully-­‐integrated
drug
development
plaTorm

• § Transi.oning
  from
  plaTorm
  to
  product
  focussed
  company

§ Well
posi.oned
to
create
mul.ple
commercialisa.on opportuni.es.

==> picture [130 x 29] intentionally omitted <==

20

Dr.
Richard
Hopkins Chief
Execu7ve
Officer Tel:
+61
8
9489
7777 Fax:
+61
8
9489
7700 Mobile:
+61
405
656
868 richardh@phylogica.com

==> picture [130 x 29] intentionally omitted <==

**Contact

Details**

www.phylogica.com

Dr.
Paul
WaQ Chief
Scien7fic
Officer Tel:
+61
8
9489
7777 Fax:
+61
8
9489
7700 Mobile:
+61
421
550
213 paulw@phylogica.com

21